Expert analysis on the Canadian and global life sciences sector

Innovation, Science and Economic Development Canada (ISED), along with partner Departments and agencies including Health Canada and the Public Health Agency of Canada, has played a central role in developing and implementing Canada’s Biomanufacturing and Life Sciences Strategy, helping to ensure the domestic life sciences ecosystem is positioned to respond to future health threats. In support of this work, ISED, through its Office of Life Sciences and Biomanufacturing Readiness (OLSBR), regularly advances research and analysis relating to global technology and industrial trends in the life sciences, business analytics, investment activity (domestic and global), domestic assets and capacity assessments, and beyond, related to the production of vaccines, therapeutic drugs, and other Medical Countermeasures (MCMs), as well as the life sciences sector at large. This analysis informs policies, approaches, and investment prioritization undertaken under the Strategy, and through such sector support tools as Canada’s Strategic Innovation Fund. ISED requires the services of a Contractor to carry out detailed analysis to support the Department’s mandate of strengthening the domestic life sciences ecosystem and advancing MCM preparedness. This includes, but is not limited to, analysis of the sectors responsible for the development and production of technologies and products within the life sciences sector, including biologics, MCMs, raw materials, equipment and all supply chain components necessary across the value chain, both domestically and internationally. The expertise required must provide, notably, in-depth economic analysis on sector trends and developments, actions taken, underway, or being considered by other governments, in-depth analytics related to corporate performance, expert analysis of complex manufacturing supply chains and production practices, both in Canada and abroad, and beyond as required by ISED.